Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Fan, Yueyue; Hao, Wenyan; Cui, Yuexin; Chen, Mengyu; Chu, Xiaoyang; Yang, Yang; Wang, Yuli; Gao, Chunsheng

doi:10.3390/molecules26165103

Cited by 26 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Red blood cell (Hu et al, 2011;Pei et al, 2018;Wan et al, 2018;Xuan et al, 2018;Bidkar et al, 2019;Huang et al, 2019;Lee et al, 2019;Wang et al, 2020a;Wang et al, 2020c;Li and Zhang, 2020;Peng et al, 2020;Zhai et al, 2020;Wu et al, 2021b;Gao et al, 2021) Hu et al, Wang et al, Li et al, Lee et al, Wu et al, Huang et al, Xuan et al, Peng et al, Bidkar et al, Wang et al, Wan et al, Zhai et al, Pei et al, Gao et al Platelet (Xu et al, 2018;Chen et al, 2019;Wang et al, 2019;Jiang et al, 2020b;Wu et al, 2020;Li et al, 2021a;Lyu et al, 2021) Wu et al, Li et al, Chen et al, Wang et al, Jiang et al, Lyu et al, Xu et al Neutrophil (Wang et al, 2021a;Zhao et al, 2021b;Zhang et al, 2021) Zhang et al, Wang et al, Zhao et al Cancer cell (Jiang et al, 2020a;Wang et al, 2020b;Wang et al, 2020d;Chen et al, 2021a;Zhao et al, 2021a;Fan et al, 2021;Jin et al, 2021;Liu et al, 2021;Shen et al, 2021;Xu et al, 2021) Wang et al, Liu et al, Li et al, Chen et al, Zhao et al, Shen et al, Fan et al, Jiang et al, Wang et al, Jin et al, Xu et (Parodi et al, 2013;Evangelopoulos et al, 2016;Palomba et al, 2016;Molinaro et al, 2018;…”

Section: Source Cell References Authormentioning

confidence: 99%

“…Cell membranes that separate the cell cytoplasm from the outer environment are phospholipid bilayer semi-permeable structures with embedded and bound proteins and other motifs. The isolation of plasma membranes from source cells mainly involves a combination of hypotonic lysis, mechanical membrane fragmentation, and emptying the intracellular contents through differential centrifugation (Parodi et al, 2013;Gao et al, 2016;Zhang et al, 2017;Pitchaimani et al, 2018;Yang et al, 2018;Cao et al, 2020;Gong et al, 2020;Poudel et al, 2020;Wu et al, 2020;Chen et al, 2021a;Li et al, 2021a;Wang et al, 2021a;Zhao et al, 2021a;Wu et al, 2021c;Fan et al, 2021;Liu et al, 2021;Shen et al, 2021;Zhang et al, 2021). Generally, cell membrane vesicles used for core NPs coating are obtained using a combination of hypotonic lysis buffer to lyse cells or the freeze-thaw method to obtain cell membranes; mechanical disruption of cell membranes using a dounce homogenizer, sonication, and/or extrusion, and finally, differential ultracentrifugation to obtain membrane vesicles (Parodi et al, 2013;Gao et al, 2016;Zhang et al, 2017;Liu et al, 2018;Pitchaimani et al, 2018;Xuan et al, 2018;Yang et al, 2018;Bidkar et al, 2019;Huang et al, 2019;Lee et al, 2019;Wang et al, 2020b;Cao et al, 2020;Wang et al, 2020c;Peng et al, 2020;Poudel et al, 2020;Wu et al, 2020;Chen et al, 2021a;…”

Section: Components and Development Of Cell Membrane-camouflaged Npsmentioning

confidence: 99%

“…The core constituents of cell membrane-camouflaged NPs can be organic, inorganic, or organic-inorganic hybrid nanosystems (Attia et al, 2019;Dash et al, 2020;Wu et al, 2021a;Castro et al, 2021;Jha et al, 2021). Typically, the core of the NP, which must be delivered and released at the target site, consists of its therapeutic agent and framework, which are shielded by cell membranes isolated from source cells (Gao et al, 2016;Zhang et al, 2017;Pitchaimani et al, 2018;Yang et al, 2018;Cao et al, 2020;Gong et al, 2020;Poudel et al, 2020;Wu et al, 2020;Chen et al, 2021a;Li et al, 2021a;Wang et al, 2021a;Zhao et al, 2021a;Wu et al, 2021c;Fan et al, 2021;Shen et al, 2021). Frontiers in Bioengineering and Biotechnology frontiersin.org Pitchaimani et al, 2018;Bidkar et al, 2019;Wang et al, 2019;Cao et al, 2020;Poudel et al, 2020;Wu et al, 2020;Wang et al, 2021a;Liu et al, 2021;Ma et al, 2021;Zhang et al, 2021;Cai et al, 2022).…”

Section: Cores Of Cell Membranecamouflaged Npsmentioning

confidence: 99%

“…Biomimetic NPs consist of either material-based core NPs coated the biomimetic membrane or biomimetic membrane itself acting as a therapeutic cargo carrier (Attia et al, 2019;Dash et al, 2020;Jha et al, 2021). Biomimetic NPs camouflaged with cell membrane can exhibit cell-like behaviors, potentially affording them a prolonged circulation time (Hu et al, 2011;Liu et al, 2018;Xuan et al, 2018;Bidkar et al, 2019;Huang et al, 2019;Lee et al, 2019;Wang et al, 2020a;Wang et al, 2020b;Wang et al, 2020c;Dash et al, 2020;Li and Zhang, 2020;Peng et al, 2020;Wu et al, 2021b), immune escape (Pitchaimani et al, 2018;Cao et al, 2020;Wang et al, 2021a;Liu et al, 2021;Zhang et al, 2021), and/or increased targeting abilities (Parodi et al, 2013;Gao et al, 2016;Zhang et al, 2017;Pitchaimani et al, 2018;Yang et al, 2018;Bidkar et al, 2019;Cao et al, 2020;Wang et al, 2020c;Gong et al, 2020;Poudel et al, 2020;Wu et al, 2020;Chen et al, 2021a;Li et al, 2021a;Wang et al, 2021a;Zhao et al, 2021a;Wu et al, 2021c;Fan et al, 2021;Liu et al, 2021;Shen et al, 2021;Zhang et al, 2...…”

Section: Introductionmentioning

confidence: 99%

“…The first to be developed biomimetic NPs were red blood cell (RBC) membrane-camouflaged NPs (Hu et al, 2011;Huang et al, 2019;Castro et al, 2021). Since the successful proof-ofconcept study that using cloaking NPs with cellular membranes isolated from freshly harvested erythrocytes and transferring bioactive cellular components to the surface of synthetic materials in order to confer unique functions not otherwise attainable through other bioconjugation techniques a decade ago, many source cells have been used for the fabrication of cellular membrane-camouflaged NPs (Table 1), including erythrocytes (Hu et al, 2011;Liu et al, 2018;Xuan et al, 2018;Huang et al, 2019;Lee et al, 2019;Wang et al, 2020a;Li and Zhang, 2020;Peng et al, 2020;Wu et al, 2021b), neutrophils (Wang et al, 2021a;Zhang et al, 2021), macrophages (Parodi et al, 2013;Cao et al, 2020;Poudel et al, 2020), natural killer (NK) cells (Pitchaimani et al, 2018), cytotoxic T cells (Zhang et al, 2017), stem cells (Gao et al, 2016;Yang et al, 2018), platelets (Wu et al, 2020;Li et al, 2021a), and cancer cells Chen et al, 2021a;Zhao et al, 2021a;Fan et al, 2021;Shen et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Research update on cell membrane camouflaged nanoparticles for cancer therapy

Wang

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cell membrane-camouflaged biomimetic functionalization of nanoparticles has emerged as a promising strategy for cancer theranostics. These cell membranes used for camouflaging are generally isolated from natural or engineered erythrocytes, neutrophils, macrophages, T lymphatic cells, stem cells, and cancer cells. The camouflaging strategy of coating nanoparticles with cell membranes allows for tumor homotypic targeting through self-recognition as source cells, immune evasion, and a prolonged blood circulation time, thereby improving the effective payload delivery and tumor therapy. More so, some engineered cell membranes with functionalized peptides, proteins and moieties on membrane surface can be transferred for therapy in the same time. In this review, we summarize the latest research on various types of cell membrane-camouflaged nanoparticles aimed at anti-cancer therapy, focusing on the biological advantages of different cell membranes, constitutions of nanoparticles, fabrication processes, key findings, potential therapies, and discuss the major challenges and future opportunities.

show abstract

Section: Source Cell References Authormentioning

confidence: 99%

Section: Components and Development Of Cell Membrane-camouflaged Npsmentioning

confidence: 99%

Section: Cores Of Cell Membranecamouflaged Npsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Research update on cell membrane camouflaged nanoparticles for cancer therapy

Wang

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Cancer Cell Membrane‐Based Materials for Biomedical Applications

Lu,

Fan,

Wang

et al. 2023

Small

View full text Add to dashboard Cite

The nanodelivery system provides a novel direction for disease diagnosis and treatment; however, its delivery effectiveness is restricted by the short biological half‐life and inadequate tumor targeting. The immune evasion properties and homologous targeting capabilities of natural cell membranes, particularly those of cancer cell membranes (CCM), have gained significant interest. The integration of CCM and nanoparticles has resulted in the emergence of CCM‐based nanoplatforms (CCM‐NPs), which have gained significant attention due to their unique properties. CCM‐NPs not only prolong the blood circulation time of core nanoparticles, but also direct them for homologous tumor targeting. Herein, the history and development of CCM‐NPs as well as how these platforms have been used for biomedical applications are discussed. The application of CCM‐NPs for cancer therapy will be described in detail. Translational efforts are currently under way and further research to address key areas of need will ultimately be required to facilitate the successful clinical adoption of CCM‐NPs.

show abstract

Cell Membrane Camouflaged Biomimetic Nanoparticles as a Versatile Platform for Brain Diseases Treatment

Wang,

Yang,

et al. 2024

Small Methods

View full text Add to dashboard Cite

Although there are various advancements in biomedical in the past few decades, there are still challenges in the treatment of brain diseases. The main difficulties are the inability to deliver a therapeutic dose of the drug to the brain through the blood‐brain barrier (BBB) and the serious side effects of the drug. Thus, it is essential to select biocompatible drug carriers and novel therapeutic tools to better enhance the effect of brain disease treatment. In recent years, biomimetic nanoparticles (BNPs) based on natural cell membranes, which have excellent biocompatibility and low immunogenicity, are widely used in the treatment of brain diseases to enable the drug to successfully cross the BBB and target brain lesions. BNPs can prolong the circulation time in vivo, are more conducive to drug aggregation in brain lesions. Cell membranes (CMs) from cancer cells (CCs), red blood cells (RBCs), white blood cells (WBCs), and so on are used as biomimetic coatings for nanoparticles (NPs) to achieve the ability to target, evade clearance, or stimulate the immune system. This review summarizes the application of different cell sources as BNPs coatings in the treatment of brain diseases and discusses the possibilities and challenges of clinical translation.

show abstract

Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Cited by 26 publications

References 41 publications

Research update on cell membrane camouflaged nanoparticles for cancer therapy

Research update on cell membrane camouflaged nanoparticles for cancer therapy

Cancer Cell Membrane‐Based Materials for Biomedical Applications

Cell Membrane Camouflaged Biomimetic Nanoparticles as a Versatile Platform for Brain Diseases Treatment

Contact Info

Product

Resources

About